Newswise — BOSTON – March 29, 2011 – Over time, diabetes can wreak havoc on the body’s eyes, cardiovascular system, kidneys and nerves. A major study by Joslin Diabetes Center researchers, however, has found that some people who have survived diabetes for many decades exhibit remarkably few complications—a discovery that points toward the presence of protective factors that guard against the disease's effects.
The scientists studied 351 participants in the Joslin 50-Year Medalist study, which examines people who have lived with type 1 diabetes for 50 years or more. Among this population, 43% are free from advanced diabetic eye complications, 87% from kidney disease, 39% from nerve disease and 52% from cardiovascular disease.
The surprising number of Medalists without complications “is strong evidence that there are protective molecular, physiologic or genetic mechanisms that, in these fortunate individuals, fight against the toxic effects of high blood sugars over many decades,” says Jennifer Sun, M.D., first author on the paper published in Diabetes Care.
As a group, the Joslin Medalists are very careful about controlling their blood glucose levels. However, within a reasonable range of glucose control, the study found that freedom from complications does not appear to correlate with how well these people controlled the blood sugar levels that go awry in diabetes. This conclusion differs from results shown in every other major recent study of diabetes management.
Clues to this protection may be found in analyses of a family of proteins called advanced glycation end products (AGEs), which are increased by high blood sugar levels. In the study, subjects who exhibited two specific AGEs were more than seven times as likely to have any complication. But this study also demonstrated for the first time that a combination of two other AGEs is associated with protection against eye disease.
Additionally, the researchers found a group of Medalists, followed at Joslin’s Beetham Eye Institute, whose diabetic eye complications stabilized after 17 years at a mild stage rather than continuing to worsen as expected. This finding again indicated that protective factors are present in this group.
The Joslin Medalist study has gathered data on more than 600 people and is running a broad series of investigations into what guards so many of them from complications.
Moreover, these diabetes veterans can provide other important lessons, as Dr. Sun points out.
“Insights from the Medalist Study are great motivators for patients who have just been diagnosed with diabetes or are early in the disease, particularly younger kids and adolescents,” she says. “We can tell these patients that we encourage them to control their blood sugars and get their recommended diabetes care, because they can live many decades with excellent vision and the chance to avoid other severe complications.”
Senior author on the paper is George King, M.D., Joslin’s chief scientific officer and head of the Dianne Nunnally Hoppes laboratory. Other contributors include Hillary Keenan, Jerry Cavallerano, Alessandro Doria and Lloyd Paul Aiello of Joslin; Bela Asztalos and Ernst Schaefer of Tufts University; and David Sell, Christopher Strauch and Vincent Monnier of Case Western Reserve University. Lead funders include the Juvenile Diabetes Research Foundation, the National Institutes of Health, the Massachusetts Lions Foundation, the Brehm Foundation, the Thomas J. Beatson, Jr. Foundation and Eli Lilly.
About Joslin Diabetes Center
Joslin Diabetes Center is the world's preeminent diabetes research and clinical care organization. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real hope and progress toward diabetes prevention and a cure. Founded in 1898 by Elliott P. Joslin, M.D., Joslin is an independent, nonprofit institution affiliated with Harvard Medical School. For more information about Joslin, visit www.joslin.org. Keep up with Joslin on Facebook at www.facebook.com/joslindiabetescenter and follow on Twitter at twitter.com/JoslinDiabetes.
RSS